Acid-producing propionibacterium BL8 with hypoglycemic and anti-aging functions and application of acid-producing propionibacterium BL8

Abstract

The invention relates to the field of microorganisms, and provides an acid-producing propionibacterium BL8 with hypoglycemic and anti-aging functions and application of the acid-producing propionibacterium BL8, the acid-producing propionibacterium BL8 is preserved in China General Microbiological Culture Collection Center on December 20, 2024, and the preservation number is CGMCC No. 33134. The acid-producing propionibacterium BL8 disclosed by the invention can be used for inhibiting the activity of DPP4, promoting insulin secretion of INS-1, and inhibiting the activity of acetylcholin esterase and excellent cellulase activity. The blood sugar can be reduced; the memory is improved, and the Alzheimer disease is prevented and relieved; and the traditional Chinese medicine composition has relatively high research and application values in the aspects of reducing blood sugar and resisting aging.

Description

Technical Field

[0001] The present invention relates to the field of microorganisms, and in particular to a strain of Propionibacterium acidophilus BL8 with blood sugar-lowering and anti-aging functions and applications thereof. Background Art

[0002] Propionibacterium acidogenes is Propionibacterium Microorganisms of the genus. Polymorphic rods, often rod-shaped with rounded or pointed ends; some cells are spherical, forked, or branched, but not filamentous. Cells occur singly, in pairs, or in short chains, forming V or Y shapes, or in square arrangements. They are Gram-positive, non-motile, and non-spore-forming. They are facultative anaerobes with varying degrees of oxygen tolerance; most strains can grow in slightly oxygen-deficient air. They can ferment glucose to produce propionic acid, acetic acid, and CO2. They are primarily found in cheese and dairy products.

[0003] Currently, there are few reports on Propionibacterium acidophilus, and even fewer studies on its probiotic properties and metabolic mechanisms, which to some extent hinders its development and utilization. Therefore, it is necessary to further explore the characteristics of Propionibacterium acidophilus, determine its efficacy based on the strain's functions and probiotic metabolites, and clarify its application prospects. In summary, the research and application of Propionibacterium acidophilus has broad potential for development. Summary of the Invention

[0004] The present invention aims to solve, at least to some extent, at least one of the technical problems existing in the prior art. To this end, the present invention provides a Propionibacterium acidophilum, a fermentation broth, a bacterial suspension, a food, a medicine, a health product, a feed, or an additive, and applications thereof. The novel strain of Propionibacterium acidophilum screened and obtained by the present invention has the ability to inhibit DPP4 activity, promote INS-1 insulin secretion, inhibit acetylcholinesterase activity, and exhibit superior cellulase activity, thereby lowering blood sugar, improving memory, preventing and alleviating Alzheimer's disease, promoting cellulose absorption, and improving constipation. The novel strain has high research and application value in the areas of blood sugar reduction and anti-aging.

[0005] To this end, in the first aspect of the present invention, the present invention provides a Propionibacterium acidogenicum ( Propionibacterium acidipropionici According to an embodiment of the present invention, the deposit number of the Propionibacterium acidogenicum BL8 is CGMCC No.33134.

[0006] Collection information: Strain name: Propionibacterium acidogenicum ( Propionibacterium acidipropionici ) Deposit date: December 20, 2024 Depository: General Microbiology Center of China Culture Collection Administration Deposit number: CGMCC No.33134 In a second aspect of the present invention, a fermentation broth is provided. According to an embodiment of the present invention, the fermentation broth comprises the aforementioned Propionibacterium acidogenicum BL8.

[0007] In a third aspect of the present invention, a bacterial suspension is provided. According to an embodiment of the present invention, the bacterial suspension comprises the aforementioned Propionibacterium acidogenicum BL8.

[0008] In a fourth aspect, the present invention provides a composition. According to an embodiment of the present invention, the composition comprises at least one of the Propionibacterium acidogenicum BL8 described in the first aspect, the fermentation broth described in the second aspect, and the bacterial suspension described in the third aspect.

[0009] In the fifth aspect of the present invention, the present invention proposes the use of the Propionibacterium acidogenicum BL8 described in the first aspect, the fermentation broth described in the second aspect, the bacterial suspension described in the third aspect, or the composition described in the fourth aspect in the preparation of foods, beverages, medicines, health products, feed or additives that inhibit DPP4 enzyme activity, and / or promote INS-1 to secrete insulin, and / or lower blood sugar, and / or reduce weight, and / or inhibit acetylcholinesterase, and / or produce cellulase.

[0010] In the sixth aspect of the present invention, the Propionibacterium acidogenicum BL8, the fermentation broth of the second aspect, the bacterial suspension of the third aspect, or the composition of the fourth aspect are used in the preparation of medicines for preventing, alleviating, treating or assisting in the treatment of diabetes.

[0011] In the seventh aspect of the present invention, the Propionibacterium acidogenicum BL8, the fermentation broth described in the second aspect, the bacterial suspension described in the third aspect, or the composition described in the fourth aspect are used in the preparation of anti-aging foods, beverages, medicines, health products, feeds, cosmetics or additives.

[0012] In the eighth aspect of the present invention, the Propionibacterium acidogenicum BL8, the fermentation broth described in the second aspect, the bacterial suspension described in the third aspect, or the composition described in the fourth aspect are used in the preparation of food, beverages, health products, feed or additives for improving memory, and / or in the preparation of medicines for preventing and alleviating Alzheimer's disease.

[0013] In the ninth aspect of the present invention, the Propionibacterium acidogenicum BL8, the fermentation broth of the second aspect, the bacterial suspension of the third aspect, or the composition of the fourth aspect are used in the preparation of a medicine for improving constipation.

[0014] Additional aspects and advantages of the present invention will be set forth in part in the description which follows and, in part, will be obvious from the description which follows, or may be learned by practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the following briefly introduces the drawings required for use in the embodiments. It should be understood that the following drawings only illustrate certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other relevant drawings can be obtained based on these drawings without paying any creative work.

[0016] Figure 1 :Chart of cellulose degradation results by BL8. DETAILED DESCRIPTION

[0017] Embodiments of the present invention are described in detail below, and the examples of the embodiments are shown in the accompanying drawings. It will be appreciated by those skilled in the art that the following examples are merely illustrative of the present invention and should not be construed as limiting the scope of the invention. Where specific techniques or conditions are not indicated in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. Reagents used or instruments not indicated by the manufacturer are conventional products that can be obtained commercially.

[0018] Furthermore, the terms "first" and "second" are used for descriptive purposes only and should not be understood to indicate or imply relative importance or implicitly specify the number of the technical features indicated. Thus, a feature specified as "first" or "second" may explicitly or implicitly include at least one such feature. In the description of the present invention, "plurality" or "multiple" means at least two or two, for example, two, two, three, three, etc., unless otherwise specifically defined.

[0019] In this document, the terms “include”, “have” or “include” are open expressions, that is, they include the contents specified in the present invention but do not exclude other aspects.

[0020] As used herein, the term "optionally" generally means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

[0021] The endpoints of the ranges and any values disclosed herein are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoints of each range, the endpoints of each range and individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges, which should be considered to be specifically disclosed herein.

[0022] In order to make the present invention more easily understood, certain technical and scientific terms are specifically defined below. Unless otherwise clearly defined elsewhere in this document, all other technical and scientific terms used herein have the meaning commonly understood by those skilled in the art to which the present invention belongs.

[0023] As used herein, the terms "treat" and "alleviate" refer to agents used to obtain a desired pharmacological and / or physiological effect. The effect may be preventive in terms of completely or partially preventing a disease or its symptoms, and / or therapeutic in terms of partially or completely curing a disease and / or adverse effects caused by the disease. "Treatment" as used herein covers diseases in mammals, particularly humans, and includes: (a) preventing the occurrence of a disease or condition in individuals who are susceptible to the disease but have not yet been diagnosed with the disease; (b) inhibiting the disease, such as arresting the progression of the disease; or (c) alleviating the disease, such as alleviating symptoms associated with the disease. "Treatment" as used herein covers any medication that administers a strain, fermentation broth, bacterial suspension or composition to an individual to treat, cure, alleviate, improve, reduce or inhibit the individual's disease, including but not limited to administering a strain, fermentation broth, bacterial suspension or composition described herein to an individual in need.

[0024] As used herein, the term "carrier" includes any solvent, pharmaceutical stabilizer, or combination thereof, which are known to those skilled in the art. Except where any conventional carrier is incompatible with the active ingredient, its use in therapeutic or pharmaceutical compositions is encompassed.

[0025] fermentation broth In some embodiments, the present invention provides a fermentation broth, which is fermented by the aforementioned Propionibacterium acidogenicum BL8.

[0026] It should be noted that the "fermentation broth" of the present invention refers to the solution obtained after culturing Propionibacterium acidophilus BL8 for a period of time, which mainly contains Propionibacterium acidophilus BL8 and its metabolites; or the supernatant after further treatment by centrifugation, filtration, etc., which mainly contains the metabolites of Propionibacterium acidophilus BL8.

[0027] bacterial suspension In some embodiments, the present invention provides a bacterial suspension comprising the aforementioned Propionibacterium acidogenicum BL8.

[0028] It should be noted that the bacterial suspension can be obtained by treating the above fermentation broth by means of centrifugation, resuspension, etc.

[0029] Food, beverages, medicines, health products, feed, cosmetics or additives According to an embodiment of the present invention, the above-mentioned food, beverage, medicine, health product, feed, cosmetic or additive may further include at least one of the following additional technical features: According to an embodiment of the present invention, it further comprises pharmaceutically acceptable excipients or carriers, excipients or carriers acceptable in food or health products, or excipients or carriers acceptable in animal feed.

[0030] As used herein, "acceptable in food" refers to substances or compositions that can be consumed by humans, which may be adjusted according to food requirements in different countries.

[0031] As used herein, "acceptable in health products" refers to substances or compositions that can be consumed by humans, which may be adjusted according to the health product requirements of different countries.

[0032] As used herein, "pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients of the formulation and / or the mammal to be treated therewith. Preferably, "pharmaceutically acceptable" as used herein means approved by federal regulatory agencies or national governments or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopeia for use in animals, particularly humans.

[0033] As used herein, "adjuvant or carrier acceptable in animal feed" refers to a substance or composition that can be consumed by animals, which may be adjusted according to the animal feed requirements of different countries.

[0034] As used herein, the term "pharmaceutically acceptable carrier" includes any solvent, pharmaceutical stabilizer, or combination thereof, which are known to those skilled in the art. Except where any conventional carrier is incompatible with the active ingredient, its use in therapeutic or pharmaceutical compositions is encompassed.

[0035] As used herein, the term "pharmaceutically acceptable excipient" includes any solvent suitable for the particular intended dosage form. Except to the extent that any conventional excipient is incompatible with the Propionibacterium acidogenicum BL8 disclosed herein, such as by producing any adverse biological effects or interacting in a deleterious manner with any other component of the pharmaceutically acceptable composition, their use is contemplated by the present disclosure.

[0036] According to an embodiment of the present invention, at least one of the aforementioned Propionibacterium acidogenicum BL8, fermentation broth and bacterial suspension is added or inoculated into food, beverages, health products, feed, cosmetics or additives, or added to medicines.

[0037] Illustratively, the aforementioned foods include but are not limited to: probiotic tablets, fermented dairy products (such as probiotic yogurt), probiotic solid beverages, probiotic milk powder, probiotic cheese, probiotic soy products, probiotic candies, probiotic fermented vegetables, etc.

[0038] For example, the aforementioned medicines include but are not limited to: medicines for human use and medicines for veterinary use. The aforementioned medicines for veterinary use may be for pets, livestock, or wild animals.

[0039] Illustratively, the aforementioned health care products include but are not limited to: health care products for humans and health care products for animals.

[0040] It should be noted that the characteristics and advantages described above for Propionibacterium acidogenicum BL8 are also applicable to the food, beverage, medicine, health product, feed, cosmetics or additives, and will not be repeated here.

[0041] Composition According to an embodiment of the present invention, the above composition may further include at least one of the following additional technical features: According to an embodiment of the present invention, the composition further comprises an ingestible excipient and / or carrier.

[0042] According to an embodiment of the present invention, the excipient includes at least one selected from a binder, a disintegrant, a lubricant, a glidant, a stabilizer, a filler, a diluent and a sustained-release agent.

[0043] According to an embodiment of the present invention, the carrier includes at least one selected from sugars, cellulose and its derivatives, calcium phosphates, alkaline earth metal stearates, vegetable oils, nonionic surfactants, cationic surfactants, anionic surfactants, fatty alcohols and cereal hydrolyzed solids.

[0044] According to an embodiment of the present invention, the dosage form of the composition includes at least one selected from oral liquid, powder, granule, capsule, tablet, and pill.

[0045] Example 1 Isolation and identification of strains 1. Sample collection The acid-producing Propionibacterium BL8 strain was isolated from the breast milk of lactating women within the company by the strain technology platform personnel and stored at a low temperature of -80°C.

[0046] 2. Strain Isolation After a ten-fold gradient dilution of the sample, appropriate dilutions were evenly plated onto MRS medium plates. The plates were then inverted and anaerobically incubated at 37°C for 48 hours. Single colonies were then selected from the plates coated with the different gradients and transferred to culture. Finally, a strain with excellent growth properties was obtained, named BL8.

[0047] 3. Strain identification The bacterial strain BL8 of the present invention grows on solid plates grown on MRS medium. Its colonies are milky white, smooth, round, and easy to pick up. Its optimal growth pH is 6.0-7.0, and its optimal growth temperature is 35-37°C. 16S rDNA sequencing results show that the 16S rDNA sequence of BL8 shares >99% sequence homology with known standard strains of Propionibacterium acidigenicum.

[0048] Therefore, strain BL8 was identified as Propionibacterium acidogenicum ( Propionibacterium acidipropionici ), the strain BL8 was deposited in the General Microbiology Center of China Culture Collection Administration on December 20, 2024. The deposit address is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC No. 33134.

[0049] 16S rDNA sequence of Propionibacterium acidogenicum BL8:

[0050] Example 2 Preparation of Cellular Metabolites (CFS) Propionibacterium acidigenics BL8 was cultured anaerobically at 37°C in MRS medium for 18 h, and then harvested by centrifugation at 3000 rpm for 10 min at 4°C. The cells were washed twice with sterile phosphate buffered saline (PBS, pH 6.8), resuspended in PBS, and the cell concentration was adjusted to 1 × 10 9 CFU / ml, and use as bacterial suspension. Adjust the concentration to 10 9 CFU / ml of Propionibacterium acidophilus was incubated anaerobically at 37°C for 16 h, and then centrifuged at 3000 rpm for 10 min at 4°C. The supernatant was filtered through a 0.22 μm water microfiltration membrane to obtain cell metabolites and stored at -80°C.

[0051] Example 3 Inhibitory effect of Propionibacterium acidigenics BL8 on dipeptidyl peptidase-IV (DPP4) In a 96-well plate, add 25 μL of glycyl-prolyl-p-nitroaniline (1.6 mmol / L) and 25 μL of CFS to the reaction wells using a micropipette. Incubate at 37°C for 10 minutes, then add 50 μL of DPP4 (10 U / L). Incubate at 37°C for 60 minutes. Finally, add 100 μL of sodium acetate buffer (pH 4.0, 1 mol / L) to terminate the reaction. Measure the absorbance of the reaction solution at 405 nm using a microplate reader. Perform three replicates for each sample. Calculate the inhibition rate as follows: Inhibition rate (%) = {1-(A 样品 -A 样品空白 ) / (A 阳性 -A 阴性 )﹜×100 Wherein: positive is glycyl-prolyl-p-nitroaniline + Tris-HCL buffer (100 mmol / L, pH 8.0) + DPP4 + sodium acetate buffer; Negative: glycyl-prolyl-p-nitroaniline + Tris-HCL buffer (100 mmol / L, pH 8.0) + Tris-HCL buffer + sodium acetate buffer; The sample consisted of glycyl-prolyl-p-nitroaniline + sample + DPP4 + sodium acetate buffer; The sample blank consisted of glycyl-prolyl-p-nitroaniline + sample + Tris-HCl buffer (100 mmol / L, pH 8.0) + sodium acetate buffer.

[0052] Results: As shown in Table 1, compared with the blank medium MRS which had no inhibitory effect, the CFS of Propionibacterium acidogenicum BL8 had a high inhibitory effect on DPP4 enzyme activity, with an inhibition rate of 81.3%.

[0053] Table 1: BL8 DPP4 inhibition results

[0054] Example 4 Propionibacterium acidophilus BL8 promotes insulin secretion Cell culture: INS-1 cells (rat pancreatic islet cell carcinoma cells) were cultured in RPMI1640 complete medium (containing 10% fetal bovine serum, 1mM sodium pyruvate, 50μM mercaptoethanol, 100 μ 1g / ml streptomycin) in a 37°C, 5% CO2 incubator. Allow cells to adhere to the wall and subculture when the cell density reaches 80%-90%.

[0055] Promote insulin secretion: cultured INS-1 cells were plated at 1×10 5 CFU / ml was inoculated into 12-well plates at 1.5 ml / well. After incubation at 37°C, 5% CO2 for 24 hours, the RPMI1640 medium was discarded and the plates were gently washed twice with KRBH buffer. The cells were then pre-incubated with KRBH for 2 hours to sensitize them to glucose. Fresh KRBH buffer containing CFS was then replaced and incubated for another 1 hour. The supernatant was collected and stored at -20°C for insulin determination.

[0056] Insulin content detection: Rat insulin detection kit (Solebo, number: SEKR-0033-96T) Results: As shown in Table 2, CFS of Propionibacterium acidophilus BL8 can significantly promote the secretion of insulin by INS-1 cells.

[0057] Table 2: BL8 insulin secretion results

[0058] Example 5 Inhibitory effect of Propionibacterium acidogenes BL8 on acetylcholinesterase activity Add 2.65ml of PBS (pH 8.0), 50μL of acetylcholinesterase (AChE, 1U / ml), 100μL of dithiodinitrobenzoic acid (DTNB, 15mM), and 100μL of sample solution (CFS) to a test tube. Preheat at 37°C for 2 minutes, then add 100μL of thioacetylcholine (ATch, 15mM). After incubation at 37°C for 20 minutes, immediately add 1ml of sodium dodecyl sulfate (SDS, 0.4%) to terminate the reaction. The resulting solution is immediately measured for absorbance at 412nm. The inhibition rate is calculated as follows: Inhibition rate (%) = {A 对照 -(A 样品 -A 样品空白 )﹜ / A 对照 ×100 Wherein: Control is 2.75ml PBS (pH 8.0) + AChE + DTNB + ATch + SDS The sample is 2.65ml PBS (pH 8.0) + AChE + DTNB + 100μL sample (CFS) + ATch + SDS The sample blank is 2.65 ml PBS (pH 8.0) + AChE + DTNB + 100 μL sample background + ATch + SDS Results: As shown in Table 3, CFS of Propionibacterium acidogenes BL8 inhibited acetylcholinesterase activity with an inhibition rate of 23.33%, which can effectively prevent and alleviate Alzheimer's disease.

[0059] Table 3: Inhibition results of BL8 on acetylcholinesterase activity

[0060] Example 6 Propionibacterium acidogenicum BL8 can produce cellulase The identification and determination of the cellulose degradation ability of Propionibacterium acidophilum was carried out according to the agar diffusion method. The cellulose culture medium used was MRS agar medium + 1.5% sodium carboxymethyl cellulose. During the test, 3 μL of Propionibacterium acidophilum bacterial solution (viable cell count 1×10 9 CFU / ml), 3 μL of blank MRS medium was added to the control group, and the cells were cultured in a 37°C constant temperature anaerobic incubator for 2-3 days before Congo red staining.

[0061] Results: Compared with the control group with blank culture medium, BL8 could significantly degrade cellulose and form an obvious degradation zone ( Figure 1 ), indicating that Propionibacterium acidophilus BL8 can produce cellulase, which can effectively relieve and improve constipation in people.

[0062] Example 7 Acid resistance determination of Propionibacterium acidogenicum BL8 Propionibacterium acidophilum BL8 was inoculated into MRS broth at a 1% inoculum volume, cultured anaerobically at 37°C for 18 h, and centrifuged at 3000 rpm for 10 min at 4°C to collect the bacteria. The collected bacteria were resuspended in artificial gastric fluid (pH 2.5) and the bacterial concentration was adjusted to 10 9 CFU / ml, after anaerobic incubation at 37℃ for 0h, 2h, and 4h, the plate counts were performed to calculate the survival rate of acid-producing Propionibacterium and evaluate acid tolerance. The survival rate was calculated as shown in the formula: Survival rate (%) = number of viable bacteria at the end / number of viable bacteria at time 0 × 100 Results: In artificial gastric fluid, the survival rate of BL8 was 53.5% after 4 hours (Table 4), indicating good acid tolerance.

[0063] Table 4: BL8 acid resistance results

[0064] Example 8 Bile salt tolerance determination of Propionibacterium acidogenicum BL8 Propionibacterium acidophilum BL8 was inoculated into MRS broth at a 1% inoculum volume, cultured anaerobically at 37°C for 18 h, and centrifuged at 3000 rpm for 10 min at 4°C to collect the bacteria. The collected bacteria were resuspended in simulated intestinal fluid at pH 8.0 containing 0.1%, 0.2%, or 0.3% bile salts and a pH of 8, and the bacterial concentration was adjusted to 10 9 The CFU / ml was counted on the plates after anaerobic incubation at 37°C for 0 h, 2 h, and 4 h, and the survival rate of Propionibacterium acidogenes was calculated to evaluate bile salt tolerance.

[0065] Results: In bile salt solutions with concentrations of 0.1%, 0.2%, and 0.3%, the survival rate of BL8 reached over 90% after 4 hours (Table 5), indicating good bile salt tolerance. The survival rate was calculated as follows: Survival rate (%) = number of viable bacteria at the final time / number of viable bacteria at time 0 × 100.

[0066] Table 5: Bile salt tolerance results of BL8

[0067] Example 9 Determination of hydrophobicity of Propionibacterium acidogenicum BL8 Propionibacterium acidophilum BL8 was inoculated into MRS broth at a 1% inoculum volume, cultured anaerobically at 37°C for 18 hours, and centrifuged at 4°C and 3000 rpm for 10 minutes to collect the bacteria. Wash twice with sterile PBS (pH 8.0). The bacterial solution concentration was adjusted to an OD600 between 0.6 and 1. 4 ml of the adjusted bacterial solution was taken and mixed with 0.5 ml of xylene and ethyl acetate respectively. After vortexing for 2 minutes, it was allowed to stand at room temperature for 15 minutes. When stratification occurred, the water layer was carefully aspirated and the OD value of the aqueous phase was measured at a wavelength of 600 nm. The hydrophobicity was calculated as shown in the formula: Cell surface hydrophobicity (%) = (OD initial - OD final) / OD initial × 100 Results: The hydrophobicity of BL8 in xylene was 25.3% and in ethyl acetate was 29% (Table 6), indicating that it is a moderately hydrophobic strain.

[0068] Table 6: BL8 hydrophobicity results

[0069] In the description of this specification, reference to the terms "one embodiment," "some embodiments," "an embodiment," or "a specific embodiment" means that the specific features, structures, materials, or characteristics described in conjunction with the embodiment are included in at least one embodiment of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment. Moreover, the specific features, structures, materials, or characteristics described can be combined in any suitable manner in any one or more embodiments. In addition, those skilled in the art may combine and combine different embodiments and features of different embodiments described in this specification without any contradiction.

[0070] Although the embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and are not to be construed as limitations on the present invention. A person skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention.

Claims

1. A strain of Propionibacterium acidophilum ( Propionibacterium acidipropionici ) BL8, characterized in that, The acid-producing Propionibacterium BL8 was deposited in the General Microbiology Center of the China Culture Collection Administration on December 20, 2024, with the deposit number CGMCC No.33134.

2. A fermentation broth, characterized in that: The fermentation broth is obtained by fermenting the Propionibacterium acidogenicum BL8 according to claim 1.

3. A bacterial suspension, characterized in that The bacterial suspension comprises the Propionibacterium acidogenicum BL8 according to claim 1.

4. A composition, characterized in that The composition comprises at least one of the Propionibacterium acidogenicum BL8 according to claim 1, the fermentation broth according to claim 2, and the bacterial suspension according to claim 3.

5. The composition according to claim 4, characterized in that The composition further comprises auxiliary materials and / or carriers.

6. Use of the Propionibacterium acidogenicum BL8 according to claim 1, the fermentation broth according to claim 2, the bacterial suspension according to claim 3, or the composition according to claim 4 in the preparation of foods, beverages, medicines, health products, feeds, or additives that inhibit DPP4 enzyme activity, and / or promote insulin secretion by INS-1, and / or lower blood sugar, and / or reduce weight, and / or inhibit acetylcholinesterase, and / or produce cellulase.

7. Use of the Propionibacterium acidogenicum BL8 according to claim 1, the fermentation broth according to claim 2, the bacterial suspension according to claim 3, or the composition according to claim 4 in the preparation of a medicament for preventing, alleviating, treating or assisting in the treatment of diabetes.

8. Use of the Propionibacterium acidogenicum BL8 according to claim 1, the fermentation broth according to claim 2, the bacterial suspension according to claim 3, or the composition according to claim 4 in the preparation of anti-aging foods, beverages, medicines, health products, feeds, cosmetics, or additives.

9. Use of the Propionibacterium acidogenicum BL8 according to claim 1, the fermentation broth according to claim 2, the bacterial suspension according to claim 3, or the composition according to claim 4 in preparing foods, beverages, health products, feeds, or additives for improving memory, and / or in preparing medicines for preventing and alleviating Alzheimer's disease.

10. Use of the Propionibacterium acidogenicum BL8 according to claim 1, the fermentation broth according to claim 2, the bacterial suspension according to claim 3, or the composition according to claim 4 in the preparation of a medicament for improving constipation.

Images